Fluocinolone acetonide ‘effective adjunct’ for chronic uveitis
Click Here to Manage Email Alerts
A real-world efficacy study of EyePoint Pharmaceuticals’ Yutiq fluocinolone implant in eyes with chronic noninfectious uveitis demonstrated stable visual acuity trending toward improvement at 6 months, according to a presenter.
“We found it is a convenient and effective adjunct for patients with low-grade chronic uveitis to improve macular edema and allow for further steroid-sparing effect,” Hans W. Andrews, MD, said at the virtual American Academy of Ophthalmology annual meeting.
In a single-center, retrospective, consecutive case series chart review of 103 eyes of 68 patients treated with fluocinolone acetonide 0.18 mg injectable intravitreal implant, Andrews and colleagues found suppression of disease activity, improvement of macular edema and a decrease in the need for systemic steroid or immunotherapy.
The mean age of participants was 59 years, and 51.5% of patients presented with bilateral uveitis. Twenty-three percent of patients had an associated systemic inflammatory disease. The most common type of uveitis was posterior, in 44.7% of eyes, and 15% of eyes had active disease at baseline.
Median visual acuity improved from 0.40 logMAR at baseline to 0.24 logMAR at 6 months. Macular edema was present in 22% of eyes at baseline; at 6 months, macular edema was present in 13.4% of eyes. In 53% of patients at 6 months, oral prednisone dosage was decreased or the need for immunotherapy was completely discontinued.
Collapse
Andrews HW. Real-world therapeutic efficacy of fluocinolone acetonide 0.18 mg injectable intravitreal implant in chronic uveitis. Presented at: American Academy of Ophthalmology annual meeting; Nov. 13-15, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts